N
AUTL

Nuveen’s Autolus Therapeutics AUTL Stock Holding History

Nuveen’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-28,267
Closed -$928K – 1041
2018
Q4 		$928K Sell
28,267
-11,009
-28% -$362K 0.01% 731
2018
Q3 		$1.21M Buy
39,276
+8,215
+26% +$222K 0.01% 733
2018
Q2 		$832K Buy
+31,061
New +$821K 0.01% 776

Other funds holding AUTL

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Nuveen's AUTL Position: Q1 2019 in Review

Nuveen sold out of Autolus Therapeutics (AUTL) in Q1 2019, closing a stake of 28,267 shares — an estimated $928K sold.

Nuveen first reported a position in AUTL in Q2 2018 and held it in 3 quarters. The position peaked at $1.21M in Q3 2018. 35 funds tracked by Wall St. Rank hold AUTL as of Q1 2019.

  • Nuveen reported no remaining Autolus Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Nuveen sold 28,267 Autolus Therapeutics shares in Q1 2019, an estimated $928K.
  • Nuveen first reported a position in Autolus Therapeutics in Q2 2018 and held it in 3 quarters.
  • Nuveen's Autolus Therapeutics position peaked at $1.21M in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2019.

Based on Nuveen's 13F filing for Q1 2019, filed 14 May 2019.